Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.30 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224024 | 1.00 | FDPS (0.31) | FDPSMBTD1L3MBTL3 | |
| SCHEMBL3459618 | 1.00 | FDPS (0.31) | FDPSMBTD1L3MBTL3 | |
| SCHEMBL3458961 | 1.00 | FDPS (0.31) | FDPSMBTD1L3MBTL3 | |
| Water SCHEMBL8500887 | 0.98 | FDPS (0.30) | FDPS | |
| Hydrochloric Acid SCHEMBL3459441 | 0.98 | FDPS (0.30) | FDPS | |
| SCHEMBL25674523 | 0.90 | — | — | |
| SCHEMBL25674524 | 0.90 | — | — | |
| SCHEMBL7860178 | 0.78 | MEN1 (0.33) | FDPSMBTD1L3MBTL3 | |
| SCHEMBL7797082 | 0.76 | MMP2 (0.37) | FDPS | |
| SCHEMBL8712375 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781418-B2 | enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid; osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis; enhanced inhibitory effect on farnesyl pyrophosphate synthase | ISIS INNOVATION LTD. (GB) | 2010-08-24 | — | — | US | claimed |
| US-5393746-A | Bone disorders | P&G PHARMACEUTICALS, INC. (US) | 1995-02-28 | — | — | US | claimed |
| US-5137880-A | Treatment for osteoporosis, pagents disease arthritis | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-08-11 | — | — | US | claimed |
| EP-0273514-B1 | NOVEL BICYCLIC DIPHOSPHONATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-12-12 | — | — | EP | claimed |
| US-4868164-A | OSTEOPOROSIS, ARTHRITIS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1989-09-19 | — | — | US | claimed |
| EP-0273514-A1 | Novel bicyclic diphosphonate compounds and pharmaceutical compositions | Norwich Eaton Pharmaceuticals, Inc. (US) | 1988-07-06 | — | — | EP | claimed |
| EP-2089403-B1 | (1R,6S)-2-AZABICYCLO[4.3.0] NONANE-8,8-DIPHOSPHONIC ACID AND ITS USE IN TREATING OR PREVENTING BONE DISORDERS, FOR EXAMPLE, OSTEOPOROSIS OR PAGET'S DISEASE | ISIS INNOVATION (GB) | 2014-05-07 | — | — | EP | disclosed |
| US-7781418-B2 | enantiomerically pure (1R,6S)-2-Azabicyclo-[4.3.0]nonane-8,8-diphosphonic acid; osteoporosis, osteolytic bone metastasis, rheumatoid arthritis and osteoarthritis; enhanced inhibitory effect on farnesyl pyrophosphate synthase | ISIS INNOVATION LTD. (GB) | 2010-08-24 | — | — | US | disclosed |
| EP-2089403-A1 | (1R,6S)-2-AZABICYCLO[4.3.0] NONANE-8,8-DIPHOSPHONIC ACID AND ITS USE IN TREATING OR PREVENTING BONE DISORDERS, FOR EXAMPLE, OSTEOPOROSIS OR PAGET'S DISEASE | The Procter & Gamble Company (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090069272-A1 | Composition for treating bone disorders | THE PROCTER & GAMBLE COMPANY AND UNIVERSITY OF ROCHESTER (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008076417-A1 | (1R,6S)-2-AZABICYCLO[4.3.0] NONANE-8,8-DIPHOSPHONIC ACID AND ITS USE IN TREATING OR PREVENTING BONE DISORDERS, FOR EXAMPLE, OSTEOPOROSIS OR PAGET'S DISEASE | THE PROCTER & GAMBLE COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-0643716-B1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMA (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5869471-A | Methods for the treatment of arthritis using phosphonates and NSAIDS | THE PROCTOR & GAMBLE COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| US-5393746-A | Bone disorders | P&G PHARMACEUTICALS, INC. (US) | 1995-02-28 | — | — | US | disclosed |
| WO-1993024497-A1 | THIO-SUBSTITUTED CYCLIC PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993024499-A1 | QUATERNARY NITROGEN-CONTAINING PHOSPHONATE COMPOUNDS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| US-5137880-A | Treatment for osteoporosis, pagents disease arthritis | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0273514-B1 | NOVEL BICYCLIC DIPHOSPHONATE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4868164-A | OSTEOPOROSIS, ARTHRITIS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1989-09-19 | — | — | US | disclosed |
| EP-0273514-A1 | Novel bicyclic diphosphonate compounds and pharmaceutical compositions | Norwich Eaton Pharmaceuticals, Inc. (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069272-A1 | Composition for treating bone disorders | ACP3, SOST, COL2A1 | FDPS 259/4885MBTD1 3750/4885L3MBTL3 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.